Head and neck tumor organoid biobank for modelling individual responses to radiation therapy according to the TP53/HPV status.

ABSTRACT:

Background

Head and neck cancers (HNC) represent an extremely heterogeneous group of diseases with a poorly predictable therapy outcome. Patient-derived tumor organoids (PDTO) offer enormous potential for individualized therapy testing and a better mechanistic understanding of the main HNC drivers.

Methods

Here, we have established a comprehensive molecularly and functionally characterized head and neck organoid biobank (HNOB) recapitulating the clinically relevant subtypes of TP53 mutant and human papillomavirus type 16 (HPV 16) infection-driven HNC. Organoids were exposed to radiotherapy, and responses were correlated with clinical data. Genetically engineered normal and tumor organoids were used for testing the direct functional consequences of TP53-loss and HPV infection

SUBMITTER: Issing C 

PROVIDER: S-EPMC11881459 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature